Class II — Potential Health Hazard

Potential health hazard — use of or exposure to this product may cause temporary or medically reversible adverse health consequences.

QIAstat-Dx Respiratory SARS-CoV-2 Panel (V1 and V2 Recalled by Qiagen GmbH Due to Identified a decreased performance reliability rate, Run abortions...

Date: May 19, 2023
Company: Qiagen GmbH
Status: Ongoing
Source: FDA (Device)

What You Should Do

Stop using this product immediately. Do not consume, use, or distribute it.

Return the product to the place of purchase for a full refund. If you have questions, contact Qiagen GmbH directly.

Affected Products

QIAstat-Dx Respiratory SARS-CoV-2 Panel (V1 and V2, CE IVD, not US IVD, not sold in the US.) Qualitative test intended for analyzing nasopharyngeal swab (NPS) samples from patients suspected of respiratory infection REF: 691214

Quantity: 4155 kits

Why Was This Recalled?

Identified a decreased performance reliability rate, Run abortions could cause delayed diagnosis since sample testing would have to be repeated

Where Was This Sold?

This product was distributed to 14 states: AL, CA, DE, FL, GA, ID, IN, ME, NY, NC, OR, TN, TX, DC

Affected (14 states)Not affected

About Qiagen GmbH

Qiagen GmbH has 4 total recalls tracked by RecallDetector.

Related Recalls

Data sourced from the FDA (Device). Last updated March 26, 2026. View original report